Watching Nivolumabs Balancing Act: How Immune Activation May Affect Both Safety and Efficacy in Patients With Advanced Melanoma

Published: Nov. 14, 2016, 9 p.m.

This podcast provides commentary on a large dataset describing the expected frequency, severity and kinetics of immune-related adverse events associated with nivolumab monotherapy and the expected use of corticosteroid supportive therapy together with observations relating to the associations between immune adverse events, corticosteroid use and efficacy.